Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Alchemia to pocket A$3M for R&D expenditure  Join our daily free Newsletter

MENAFN - ProactiveInvestors - Australia - 03/12/2012

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - ProactiveInvestors - Australia) Alchemia (ASX: ACL) expects to receive a total of A3 million under the Australian Government's R&D Tax Incentive for expenditure during the 2012 financial year.

Around 2 million of this relates to offshore R&D expenditure by Alchemia Oncology, while about 1 million is expected to be received for Australian R&D expenditure.

Alchemia is a small molecule biopharmaceutical company focused on its lead drug, fondaparinux " a generic version of GlaxoSmithKline's Arixtra, a synthetic anticoagulant mainly used for the prevention of deep vein thrombosis.

A successful finding relating to overseas expenditure not only applies to Alchemia's overseas phase three trial activities undertaken in the 2012 financial year, but also applies to these activities for the 2013 and 2014 financial years.

During these three financial years, the company expects to invest a total of over 20 million in the component of its phase three trial program covered by the overseas finding.

As a result, Alchemia stands to receive a 45% refundable tax credit of over 9 million across the three years, including the 2 million for the 2012 financial year.

The company has also made application to AusIndustry for a refund of its Australian R&D expenditure for the 2012 financial year, which is currently under review.

Approval of this application is expected within the next few weeks, and should net Alchemia over 1 million before the end of the year.


Product pipeline

Fondaparinux was approved by the U.S. Food and Drug Administration and launched in July 2011 in the U.S. by Alchemia's marketing partner, Dr Reddy's Laboratories.

The company achieved its first profit from the sales of the drug in the U.S. this year.

Alchemia also filed for approval in Europe in April this year.

Meanwhile, the company has spun out its oncology assets into a separate company, Alchemia Oncology.

The demerged entity is focused on developing Alchemia's HyACT technology which is designed to enhance existing drugs used for cancer chemotherapy to develop a new generation of anti-cancer drugs that demonstrate better efficacy than existing drugs.

The lead product from the HyACT platform is HA-Irinotecan for which a phase three clinical trial has been initiated in metastatic colorectal cancer.

 






  MENA News Headlines


 
Click to Apply






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help